<DOC>
	<DOCNO>NCT00171795</DOCNO>
	<brief_summary>This study design investigate efficacy safety rivastigmine compare placebo patient traumatic brain injury cognitive impairment .</brief_summary>
	<brief_title>Efficacy Safety Rivastigmine Patients With Traumatic Brain Injury Cognitive Impairment</brief_title>
	<detailed_description />
	<mesh_term>Wounds Injuries</mesh_term>
	<mesh_term>Brain Injuries</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Rivastigmine</mesh_term>
	<criteria>Traumatic brain injury confirm available brain imaging ( CT MRI ) least 52 week post injury Neuropsychologic disturbance indicate : impaired memory ( reduction 1 standard deviation ( SD ) mean California Verbal Learning Test ( CVLT ) impair executive function ( reduction 1 standard deviation ( SD ) mean Verbal Memory Learning Test ( VLMT ) Tower London Test ( ToL ) impair attention ( reduction 1 standard deviation ( SD ) mean Test Battery Attentional Performance ( TAP ) Be require sufficient education read , write , effectively communicate Be cooperative , able ingest oral medication , able complete aspect study capable , either alone aid responsible caregiver accord investigator 's judgement A current diagnosis cerebrovascular disease , primary neurodegenerative disorder , cause neuropsychologic disturbance A current diagnosis active , uncontrolled seizure disorder major depression , diagnosis may interfere patient 's response study medication An advanced , severe unstable disease type may interfere efficacy evaluation Female patient childbearing potential breastfeeding , pregnant practice nonhormonal contraception Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Traumatic brain injury ,</keyword>
	<keyword>cognitive impairment ,</keyword>
	<keyword>rivastigmine</keyword>
</DOC>